Compared with people starting topiramate, those starting GLP-1 drugs were 48% less likely to start valproate, 42% less likely to start calcitonin gene-related peptide (CGRP) monoclonal antibodies, 35% less likely to start tricyclic antidepressants, and 23% less likely to start the class of drugs called gepants
Kupujcy, dokonujc zakupu, owiadcza, e posiada odpowiedni wiedz i dowiadczenie umoliwiajce bezpieczne obchodzenie si z odczynnikami chemicznymi
In studies of people with obesity who do not have Type 2 diabetes, tirzepatide helped them lose more than 20% of their body weight on average
Some patients find that alcohol feels different while taking a GLP-1 medication, especially if they are eating less than usual
Conclusion Mazdutide and tirzepatide represent significant advancements in obesity and type 2 diabetes management, leveraging GLP-1-based mechanisms to achieve weight loss and glycaemic control